Cerecor Announces Final Efficacy Data From Phase 2 Trial Of CERC-002; Says CERC-002 Was Statistically Significant In Reducing Respiratory Failure And Mortality At Day 28 In Patients Hospitalized With COVID-19 Associated Pneumonia
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.